SLC5A2 and type 2 diabetes mellitus: Additionally, starting SGLT2 inhibitors in patients with T2DM and a history of percutaneous coronary intervention (PCI) was significantly associated with reduced risks of cardiorenal outcomes and mortality, regardless of the time since the last PCI [137].